Lineage Cell Therapeutics... (LCTX)
0.41
-0.01 (-1.63%)
At close: Apr 17, 2025, 3:59 PM
Lineage Cell Therapeutics Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 |
|---|---|---|
| Collaboration Revenues Revenue | 3.39M | 1.19M |
| Collaboration Revenues Revenue Growth | +185.26% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|
| United States Revenue | 14.7M | 3.9M | 1.16M |
| United States Revenue Growth | +277.48% | +235.78% | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.41M | 4.36M | 4.84M | 4.14M | 4.04M | 4.25M | 4.72M | 4.35M | 4.42M | 5.27M | 8.47M | 4.42M | 5.32M | 4.54M | 3.94M | 3.52M | 3.63M | 3.91M | 4.52M | 4.5M | 4.61M | 6.26M | 8.66M | 7.03M | 6.42M | 5.23M | 6.04M | 5.81M | 4.59M | 4.42M | 5.1M | 5.34M | 4.57M | 6.64M | 11.87M | 10.22M | 7.54M | 6.19M | 5.18M |
| Selling, General, and Administrative Revenue Growth | +1.08% | -9.93% | +16.86% | +2.57% | -4.90% | -10.06% | +8.65% | -1.67% | -16.09% | -37.77% | +91.43% | -16.80% | +17.22% | +15.27% | +11.92% | -3.09% | -7.16% | -13.52% | +0.33% | -2.28% | -26.35% | -27.74% | +23.13% | +9.51% | +22.86% | -13.52% | +4.01% | +26.68% | +3.71% | -13.29% | -4.53% | +16.81% | -31.07% | -44.10% | +16.13% | +35.49% | +21.97% | +19.45% | n/a |
| Research and Development Revenue | 3.17M | 2.87M | 2.99M | 3.87M | 3.74M | 3.87M | 4.18M | 4.1M | 3.59M | 3.3M | 2.99M | 24.78M | 2.81M | 2.93M | 3.39M | 2.61M | 3.57M | 2.81M | 3.34M | 3.49M | 4.27M | 5.24M | 4.96M | 3.78M | 4.88M | 6.36M | 5.93M | 4.7M | 6.56M | 6.27M | 6.49M | 7.01M | 6.42M | 8.94M | 13.73M | 12.79M | 11.43M | 9.06M | 9.32M |
| Research and Development Revenue Growth | +10.56% | -4.02% | -22.87% | +3.56% | -3.41% | -7.46% | +1.97% | +14.25% | +8.78% | +10.51% | -87.94% | +781.47% | -4.09% | -13.64% | +30.19% | -26.89% | +27.13% | -15.99% | -4.22% | -18.28% | -18.51% | +5.52% | +31.24% | -22.57% | -23.21% | +7.13% | +26.36% | -28.42% | +4.64% | -3.43% | -7.40% | +9.20% | -28.15% | -34.92% | +7.40% | +11.85% | +26.21% | -2.84% | n/a |